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Aripiprazole in the treatment of posttraumatic 
stress disorder. An open-label trial
Aripiprazol no tratamento do transtorno de estresse 
pós-traumático. Um ensaio clínico aberto
Abstract
Objective: Post traumatic stress disorder is frequent in the general population (7.8%-lifetime-USA). The selective serotonin reuptake 
inhibitors are the first choice of treatment but result in low remission rates.  This study aims to evaluate the effect of aripiprazole monotherapy 
for the treatment of post traumatic stress disorder. Method: Thirty-two patients diagnosed with post traumatic stress disorder were 
included in a 16-week open label trial of aripiprazole. They were evaluated at baseline, week 8, and 16 with the Clinician-Administered 
PTSD Scale, Beck Depression Inventory, Beck Anxiety Inventory, Medical Outcome Study Short Form 36, and Social Adjustment Scale. 
Statistical analysis were performed with an intention-to-treat approach and last observation carried forward. A general linear model for 
repeated measures comparing the factor with 3 continuous measures from baseline, 8 and 16 weeks was used. A between-subject 
factor was included Results: Nine patients discontinued the treatment. The mean aripiprazole dose was 9.6 (± 4.3) mg/day. The 
mean scores at baseline and endpoint for all measures were: Clinician-Administered PTSD Scale - 82.7 (± 23.1) and 51.4 (± 31.4) 
(F = 11.247, p = 0.001); Beck Anxiety Inventory - 31.7 (± 13.4) and 25.4 (± 18.2) (F = 8.931, p = 0.011); Social Adjustment 
Scale - 2.4 (± 0.45) and 2.27 (± 0.57) (F = 8.633, p = 0.012); Medical Outcome Study Short Form 36 - 76.6 (± 14.11) and 
94.01 (± 25.06) (F = 10.127 p = 0.007); and Beck Depression Inventory - 26.06 (± 11.6) and 21.35 (± 12.6) (F = 1.580, 
p = 0.042). In all measurements, the differences were statistically significant. Conclusions: Patients achieved a good response to 
treatment with aripiprazole, but placebo-controlled studies are needed for more accurate results.
Descriptors: Aripiprazole; Patients; Stress disorders, post-traumatic; Treatment; Randomized controlled trial
Resumo
Objetivo: O transtorno de estresse pós-traumático é um quadro prevalente (7,8%-lifetime-EUA) que provoca grande prejuízo aos 
pacientes. Os inibidores seletivos de recaptação de serotonina, medicação de primeira escolha para o tratamento, mostram baixos 
índices de remissão. Este estudo pretende apresentar uma diferente escolha de medicamento para tratar o transtorno de estresse 
pós-traumático. Método: Trinta e dois pacientes com transtorno de estresse pós-traumático receberam aripiprazol por 16 semanas. 
Foram submetidos na entrada, 8 e 16 semanas às escalas Clinician-Administered PTSD Scale, Beck Depression Inventory, Beck Anxiety 
Inventory, Medical Outcome Study Short Form 36 e Social Adjustment Scale. Foi usado o modelo linear generalizado para medidas 
repetidas comparando o fator com as três medidas contínuas nos três pontos de avaliação. Foi feita uma comparação entre sujeitos 
(grupo tratamento) usando modelo linear generalizado univariado. Usamos a intenção de tratamento e a estratégia da última observação 
com endpoint (Last Observation Carried Forward). Resultados: Nove pacientes descontinuaram antes da segunda avaliação. A dose 
média foi 9,6 (± 4,3) mg/dia. As medidas na entrada e no final do tratamento foram: Clinician-Administered PTSD Scale – 82,7 (± 
23,1) e 51,4 (± 31,4) (F = 11,247, p = 0,001); Beck Anxiety Inventory – 31,7 (± 13,4) e 25,4 (± 18,2) (F = 8,931, p = 0,011); 
Social Adjustment Scale – 2,4 (± 0,45) e 2,27 (± 0,57) (F = 8,633, p = 0,012); Medical Outcome Study Short Form 36 – 76,6 (± 
14,11) e 94,01 (± 25,06) (F = 10,127 p = 0,007); e Beck Depression Inventory – 26,06 (± 11,6) e 21,35 (± 12,6) (F = 1,580, 
p = 0,042). Em todas as medidas, as diferenças foram estatisticamente significativas. Conclusões: O aripiprazol alcançou uma boa 
resposta em pacientes com transtorno de estresse pós-traumático, mas para resultados mais acurados ainda são necessários estudos 
controlados com placebo. 
Descritores: Aripiprazol; Pacientes; Transtornos de estresse pós-traumáticos; Tratamento; Ensaios clínicos controlados aleatórios 
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Introduction
Posttraumatic Stress Disorder (PTSD) affects approximately 10% 
of the female population and 5% of males in the US.1 Data from 
the National Comorbidity Survey (NCS)1 involving a representative 
community sample of 5,877 individuals aged 15 to 54 from the 
US showed a 7.8% lifetime prevalence of PTSD. Combat exposure 
and witnessing among men, and rape and sexual molestation 
among women were the kinds of trauma most often associated 
with PTSD.
The serotonin reuptake inhibitors (SSRIs) are the recommended 
first-line therapy for the treatment of PTSD. They are effective across 
all PTSD symptom clusters and improve both quality of life and 
functional impairment.2 Despite their efficacy data, approximately 
20 to 40% of PTSD patients fail to respond to treatment. Remission 
rates with SSRIs after 12 weeks are relatively low, at 30% or less.3
Many chronic PTSD patients, especially male combat veterans, 
have a partial or minimal response to antidepressants.4 Studies 
with antidepressants indicate that PTSD among combat veterans 
is difficult to treat and often requires additional psychotropic 
medications.4
The search for new treatment options in PTSD is required 
because of the lack of an effective gold standard treatment. The 
antidepressants with dual mechanisms such as mirtazapine 
(noradrenergic and specific serotoninergic antidepressant)5 and 
venlafaxine (serotoninergic and noradrenergic reuptake inhibitor 
- SNRI)6 were associated with preliminary positive results; mood 
stabilizers and anticonvulsants were also tested7 and were shown 
to have potential for further studies.
There is growing evidence supporting the use of atypical antipsychotic 
agents as adjunctive therapy in PTSD. Olanzapine,8 risperidone9 and 
quetiapine10 were shown to improve scores of Clinician Administered 
Posttraumatic Scale (CAPS) total scale and subscales, as well as 
psychotic symptoms. In addition, there is evidence that 36-46% of 
patients with PTSD also suffer from psychotic symptoms.11 PTSD 
is associated with abnormalities in serotonin, norepinephrine, and 
dopamine systems, among others.12 Aripiprazole is a novel and 
efficacious antipsychotic with 5-HT2A antagonist effect and partial 
agonist activity at the 5-HT1A and D2 receptors.13
Lambert reported the case of five patients with PTSD who 
were treated with aripiprazole. The drug was well-tolerated and 
was effective in the management of sleep disturbances, such as 
nightmares and agitated behaviors during sleep, and was also helpful 
in the management of hyper-arousal. Except for one patient who 
experienced a paradoxical excitation response to the medication.14
Padala et al. also reported cases of success using aripiprazole to 
treat patients with PTSD, but as an adjunctive therapy.15
Recently, Villarreal et al. have reported the results of a twelve-
week, open-label, flexible dose trial of aripiprazole monotherapy 
conducted to assess the efficacy of the latter in core PTSD symptoms 
and associated psychiatric symptoms, including anxiety, depression 
and positive psychotic symptoms.11 Of twenty-two subjects with 
DSM-IV diagnosis of PTSD, fourteen completed the trial. Eight 
subjects dropped out due to side-effects. Significant improvements 
were seen on CAPS total and its subscales. Fourteen participants 
were classified as responders, defined as improvement of 20% or 
above on CAPS total score. Of the thirteen subjects who completed 
final ratings, CAPS total scores improved significantly (p = 0.011). 
Two subjects attained remission of PTSD (CAPS < 20), and three 
had a final CAPS < 26. The mean daily dose of aripiprazole 
was 12.95 mg. The most common side effect observed was 
somnolence.11
The pharmacological profile of aripiprazole and previous positive 
results led us to study drug in PTSD. Our main objective was to evaluate 
the aripiprazole monotherapy efficacy to treat PTSD symptoms.
Method
This study was conducted at the Program for Victims of Violence 
at the Department of Psychiatry of the Universidade Federal de São 
Paulo (Unifesp)-Brazil. It has been approved by the local Institutional 
Review Board.
1. Sample
The first thirty-two consecutive outpatients who met the inclusion 
and exclusion criteria and accepted to sign the consent form 
comprised the final sample. 
The inclusion criteria were: age from 18 to 60 years, diagnosis of 
PTSD according to DSM-IV criteria confirmed by structured clinical 
interview for DSM-IV (SCID-I) applied by a trained psychiatrist. 
Women with a childbearing potential had to be using a reliable 
contraceptive method during the study. The exclusion criteria were: 
diagnosis of schizophrenic disorder, delusional disorder, bipolar 
disorder, psychotic depression episode and psychoactive substance 
dependency disorder in the previous 6-month period, instable 
medical diseases and pregnancy. Fourteen patients were receiving 
a SSRI, nine combined with benzodiazepines, four combined 
with low doses of typical antipsychotics, four patients were using 
benzodiazepines alone, seven patients were drug naïve and seven 
had used psychoactive drugs in the past but were not medicated at 
the moment of evaluation. All patients (n = 18) who were receiving 
psychoactive medications at inclusion entered a washout period, 
which lasted according to the medications being taken, half-lives 
and current dosage (from one week to 5 weeks for fluoxetine to 
avoid interactions and discontinuation syndrome.
2. Main outcome measures 
Our primary outcome measure was the CAPS means and standard 
deviations at baseline and endpoint. 
A 30% decrease on CAPS scores at endpoint compared to baseline 
was defined as response criteria. 
Secondary outcome measures were improvement on depressive 
and anxiety symptoms measured by BDI and BAI scores at endpoint 
and compared to baseline, as well as improvement on quality of 
life and social adjustment measured by SF-36 and SAS scores at 
endpoint and compared to baseline.
3. Procedures
At baseline, patients were submitted to a socio-demographic 
inventory and to a psychometric evaluation, being the latter reapplied 
at weeks 8 and 16. The psychometric evaluation consisted of the 
CAPS and self-reporting instruments. CAPS validated to Brazilian 
Portuguese (manuscript under preparation) was administered by 
a trained researcher (MCPC) to measure PTSD symptoms severity. 
Self-reporting instruments included the Beck Depression Inventory 
(BDI) and the Beck Anxiety Inventory (BAI), the Medical Outcome 
Scale short form (MOS-SF-36) and the Social Adjustment Scale 
(SAS) to evaluate depressive and the anxiety symptoms severity, 
quality of life and social adjustment, respectively. 
An initial 7.5 mg single dose of aripiprazole was prescribed and 
patients were seen every two weeks. The dosage could be increased 
or decreased depending on tolerance to side-effects (the maximum 
dosage allowed was 15 mg/day). After a 16-week period, the drug 
was discontinued over a two week period.
Rev Bras Psiquiatr. 2008;30(4):358-61 
Mello MF et al.360
4. Statistical analysis
All data were analyzed using SPSS (version 13.0). For missing 
data we used the last observation carried forward strategy for an 
intention-to-treat analysis. The frequencies of nominal variables 
from all patients were calculated. CAPS scores from baseline and 
endpoint were stratified according to severity. Nominal data were 
analyzed using the chi-square test and the Fisher test when there 
were cells that counted less than five or at least one cell counted 
zero subjects. 
A univariate General Linear Model (GLM) for repeated measures 
was used to compare each of the scales as 3 continuous measures 
(baseline, week 8 and 16).The between-subject factor was defined 
as the independent variable (treatment group). The confidence level 
used for all comparisons was 5% (p < 0.05). All observed Power 
as a type II error function were presented with minimum values of 
significance for each comparison. 
Results
Thirty-two outpatients comprised the final sample. Twenty-four 
(75%) were women and 8 (25%) were men. Eighteen (56.3%) 
were married, eight (25%) were single, and six (18.7%) were 
widowed or divorced. Their mean age was 38.41 (± 10.97) 
years old, and the mean time since trauma happened was 50.87 
(± 77.21) months. Three (9.4%) patients had been victims of 
sexual abuse, four (12.5%) had been kidnapped, four (12.5%) 
had been held hostage in prison rebellions, 7 (21.88%) had 
lost a close person in homicide and 8 (18.75%), had suffered 
a homicide attempt. PTSD symptoms means duration was 
50.93 (± 77.17) months, ranging from 2 months to 30 years 
of history.
Nine (28%) patients discontinued the treatment before 
the second assessment. Six of them (18.7%) discontinued 
the medicat ion because o f  adverse events  (anx ie ty, 
psychomotor agitat ion, nausea, and insomnia). Three 
patients who abandoned treatment could not be contacted. 
Using GLM for repeated measures we did not detect 
any effect of the between subject factor (F(8,18) = 0.846; 
p = 0.613; observed power 0.260) but found a significant effect 
of CAPS (F = 13.169; p = 0.002; observed power 0.980), BAI 
(F = 5.065; p = 0.025; observed power 0.810), BDI (F = 3.895; 
p = 0.039; observed power 0.802) and SF-36 (F = 6.114; 
p = 0.018; observed power 0.867) on final outcome. 
The mean aripiprazole maximum tolerated dosage was 9.6 
(± 4.3) mg/day, with a dose range of 3.75 to 15 mg/day.
Using intention-to-treat analysis with last observation carried 
forward (LOCF) for missing values we found a CAPS mean scores 
at baseline of 82.7 (± 23.1) and 51.4 (± 31.4) on endpoint, what 
represents a 38% reduction from baseline.  When comparing the 
data using a univariate GLM, the difference between scores before 
and after treatment was statistically significant (F = 11.247, 
p = 0.001, Observed Power = 1.000). When applying a response 
criteria of 30% decrease at CAPS mean score from baseline, 17 
(53.1%) patients were classified as responders.
Considering that a CAPS score higher than 50 was still in 
the PTSD range, only six (19%) patients remitted (CAPS < 
20), and twelve (12/38%) patients had mild PTSD symptoms 
(CAPS < 39) after the treatment. For an additional analysis, 
we classified patients according to severity strata based on 
CAPS scores. At baseline strata were composed of 20 patients 
with an extremely severe PTSD (CAPS > 80), eight with 
severe PTSD (CAPS from 60 to 79), three with moderate PTSD 
(CAPS from 40 to 59), and one with a mild PTSD (CAPS 
from 20 to 39). After treatment, using LOCF, six patients 
had extremely severe PTSD, six had severe PTSD, eight had 
moderate PTSD; seven mild PTSD, and five patients had 
subclinical PTSD (CAPS < 19). Extremely severe and severe 
PTSD strata were associated at baseline and end of treatment 
(chi-square = 22.793, p < 0.030). The difference was due to 
extreme, severe and mild PTSD symptom cases. 
The mean BAI score at baseline was 31.7 (± 13.4) and 
at end-point it was 25.4 (± 18.2) (F = 8.931, p = 0.011, 
Observed Power = 0.988). The SAS mean index score at baseline 
was 2.4 (± 0.45) and at endpoint 2.27 (± 0.57) (F = 8.633, 
p = 0.012, observed power = 0.990). The MOS SF-36 mean score 
at baseline was 76.6 (± 14.11) and at endpoint 94.01 (± 25.06) 
(F =10.127, p = 0.007 observed power = 1.000). The mean 
BDI score at baseline was 26.06 (± 11.6) and at the end-point 
21.35 (± 12.6) which was shown to be a statistically significant 
difference (F = 1.580, p = 0.042, observed power = 0.830). In 
all measurements the differences between baseline and endpoint 
means were statistically significant. 
Discussion
Patients with PTSD showed a response to aripiprazole in this 
open trial with numbers that are at least comparable to those 
obtained with the first-line agents (SSRIs). Patients improved 
regarding not only specific PTSD symptoms, but also depressive 
and anxiety symptoms, social adjustment and quality of life. 
Although many patients were still symptomatic after the trial, 
some of those who tolerated medication side effects and 
completed the trial had a positive response to treatment. For 
a small number of patients the severity of PTSD or depressive 
symptoms have worsened from baseline or remained the same 
after 16 weeks of treatment. A significant number of patients 
(28%) discontinued treatment, many of which due to side effects. 
Those who discontinued had more severe depressive symptoms 
at baseline. This is a difficult-to-interpret finding as aripiprazole 
has been show to effectively treat unipolar depressive disorder, 
and was recently approved by the FDA to treat this condition. We 
could hypothesize that PTSD-depressive syndrome comorbidity 
behaves differently from unipolar depressive disorder on which 
aripiprazole was recently approved to treat.
Our results are encouraging for future prospective double-
blind, placebo-controlled, randomized trials specifically designed 
to test aripiprazole efficacy. In addition, further studies should 
identify subgroups of patients with a greater chance of better 
response, for example those with more dissociative or psychotic 
symptoms. Finally, an investigation into whether aripiprazole 
as adjunct therapy of an SSRI has a better profile than a 
monotherapy for those patients with depression disorder as 
comorbidity should be conducted. 
A weakness of this study is the length of follow-up and drug 
use continuation; as PTSD symptoms continued to improve 
slowly up to nine months after the beginning of treatment. 
Also, it is an open trial, which limited our possibility of 
drawing conclusions. Some patients had a very fast response 
to medication evaluated clinically, but some could not stand 
the gastrointestinal symptoms even with doses as low as 3.75 
mg/day; most dropouts included those presenting the most 
severe depressive symptoms, which again reinforces the need 
to evaluate specific groups of patients that will respond better 
to aripiprazole monotherapy.
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